Concomitant nephrectomy of massively enlarged kidneys and renal transplantation in autosomal dominant polycystic kidney disease

Transplant Proc. 2005 Sep;37(7):2939-40. doi: 10.1016/j.transproceed.2005.07.053.

Abstract

Objectives: We compared perioperative and intraoperative data of patients with end-stage renal disease (ESRD) due to autosomal dominant polycystic kidney disease (ADPKD) who received a renal allograft without native nephrectomy with ADPKD patients who underwent concomitant native nephrectomy of massively enlarged kidneys and renal transplantation to determine whether the latter approach is reasonable and safe.

Patients and methods: From January 1987 to December 2003, 13 patients with ESRD due to ADPKD were stratified as 6 patients who underwent bilateral and 7 patients who underwent unilateral native nephrectomy in conjunction with renal transplantation (group A), versus 20 patients with ESRD due to ADPKD underwent renal transplantation without native nephrectomy (group B). Operative time, need for intraoperative transfusion, time to oral intake, duration of hospital stay, serum creatinine level on the day of discharge, readmission rate, and postoperative complications were compared for both groups.

Results: Mean intraoperative duration was significantly longer for patients in group A, but there was no statistically significant difference in the findings between both groups.

Conclusions: Concomitant native nephrectomy of massively enlarged kidneys at the time of renal transplantation is reasonable and safe for patients with ESRD due to ADPKD.

MeSH terms

  • Adult
  • Creatinine / blood
  • Functional Laterality
  • Humans
  • Intraoperative Complications / classification
  • Kidney / pathology
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / physiology*
  • Length of Stay
  • Middle Aged
  • Nephrectomy*
  • Polycystic Kidney, Autosomal Dominant / complications
  • Polycystic Kidney, Autosomal Dominant / surgery*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Creatinine